ClinicalTrials.gg
Not yet recruitingNCT07597590Updated Oct 7, 2026

Digital Patient-Reported Assessment in Older Adults With Acute Leukemia

An interventional study of Digital Patient-Reported Assessment Pathway in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Not yet recruiting at 1 site in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Not applicable, Interventional, and Health services research

How we know

Updated Oct 7, 2026Study completion movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies in Leukemia, Myeloid, Acute with a site in Spain — 35 open to participants now, 61 under way, 22 of them phase 3. Leukemia, Myeloid, Acute · Spain.

Planned enrollment
170th of 189
20 · median 120
Started
2026
with 6 others
No phase
3 of 200
1 open now
Primary completion
2027-12
later than 35 of 60 live
Registered
200th of 200
by date

Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, this one is the 170th largest by planned enrollment of the 189 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 with no phase, reaches primary completion later than 35 of the 60 other live ones, and was the 200th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

35 of the 200 studies in Leukemia, Myeloid, Acute with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Leukemia, Myeloid, Acute with a site in Spain, or all of them as a file.
02

Study summary

This pilot study will evaluate the feasibility of implementing a structured digital patient-reported assessment pathway in adults aged 65 years or older with acute leukemia at Hospital Universitario Central de Asturias, Oviedo, Spain. Participants will complete the EORTC QLQ-C30 and FACT-Leu remotely after the baseline visit and repeat the digital assessment 8-12 weeks after individual activation of the MiAsturSalud/SESPA digital pathway. The primary outcome will be the proportion of participants answering at least 80% of the items in the baseline digital questionnaire battery within 7 days after the baseline visit. Secondary outcomes will be caregiver assistance requirement, non-completion of the planned digital follow-up assessment, and elapsed baseline questionnaire completion time. During this feasibility study, participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention. The questionnaire pathway will not generate automated clinical alerts. Usual clinical care will continue. The study is not designed to establish clinical efficacy.

Read the detailed description

This study evaluates the implementation of a digital questionnaire pathway within the institutional MiAsturSalud/SESPA platform at Hospital Universitario Central de Asturias, Oviedo, Spain. It constitutes a defined feasibility component of the broader CEImPA 2025.519 project.

The baseline digital assessment will be scheduled 48-72 hours after the baseline visit. Responses saved within 7 days after that visit will contribute to the primary outcome. The follow-up digital assessment will take place during the window of 8-12 weeks after individual activation of the digital pathway.

The questionnaire battery comprises the 30-item EORTC QLQ-C30 and the 44-item FACT-Leu, giving a total of 74 items. The platform will permit individual items to be skipped, progressively save partial responses, and allow participants to resume an incomplete assessment within the corresponding assessment window. These functions and the timestamp recording required for outcome measurement will be implemented and verified before recruitment begins.

The primary outcome will be the proportion of all enrolled participants who answer at least 80% of the baseline battery items within 7 days after the baseline visit. Meeting this criterion requires at least 60 answered items out of 74. Outcome ascertainment will use responses saved by the end of the assessment window, irrespective of formal battery submission. All enrolled participants will be included in the denominator; those with fewer than 60 answered items, including those with no recorded responses, will not meet the criterion.

The same threshold of at least 60 answered items out of 74 will define completion of the follow-up assessment within the 8-12-week window. Follow-up completion status will be determined at the end of this window, irrespective of formal battery submission. Reasons for non-completion will be recorded where ascertainable and reported separately, distinguishing technical or participation-related barriers from clinical events preventing assessment.

Elapsed baseline completion time will be measured in minutes from the first saved item response to the first time at which at least 60 distinct items have saved responses. This measure will be calculated among participants who reach the threshold within the 7-day baseline window. It will include pauses and intervals between sessions and will not be interpreted as active questionnaire completion time. Participants who do not reach the threshold will not be assigned a completion time; their number will be reported separately.

The item-completion criterion is an operational measure of implementation feasibility and is separate from the instrument-specific rules for calculating questionnaire scores. The 80% threshold is a pragmatic criterion and is not an externally validated benchmark or a stand-alone progression rule. The participant-level feasibility estimate and its 95% confidence interval will be interpreted alongside item-completion patterns, caregiver assistance, follow-up non-completion and its reasons, and elapsed time to the baseline completion threshold to identify modifications needed before a larger evaluation.

Throughout this component's baseline and follow-up period, participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention. The study questionnaire pathway will not generate automated clinical alerts or mandate treatment changes. Home monitoring and clinical-alert functions are planned for a subsequent phase and are outside the scope of this registered feasibility study. Usual clinical care will continue.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia

Keywords

  • acute leukemia
  • older adults
  • feasibility study
  • electronic patient-reported outcomes
  • digital health implementation
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years or older.
  • Confirmed diagnosis of acute leukemia of myeloid or lymphoid origin.
  • Active ambulatory follow-up in the Hematology Service at Hospital Universitario Central de Asturias.
  • Ability to understand the questionnaires and provide their own responses, independently or with practical assistance from a caregiver.
  • Access to a compatible internet-enabled digital device, either personally or through a caregiver.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment that, in the treating hematologist's clinical judgment, prevents the participant from understanding the questionnaires or providing their own responses, despite permitted practical assistance from a caregiver.
  • Clinical condition that, in the treating hematologist's judgment, precludes completion of the study procedures.
  • Persistent inability to access or use the MiAsturSalud/SESPA platform despite reasonable technical support.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Digital Patient-Reported Assessment Pathway

    Other: Digital Patient-Reported Assessment Pathway

Interventions

  • OtherDigital Patient-Reported Assessment Pathway

    Following individual activation of the MiAsturSalud/SESPA digital pathway, participants will complete the EORTC QLQ-C30 and FACT-Leu remotely. The baseline assessment will be scheduled 48-72 hours after the baseline visit, with a primary outcome assessment window extending to 7 days after that visit. A second digital assessment will be scheduled 8-12 weeks after individual pathway activation. The platform will permit skipped items, save partial responses, and allow participants to resume the baseline assessment within the 7-day window. Questionnaire item responses and timing data will be recorded, and practical caregiver assistance will be documented. The questionnaire pathway will not generate automated clinical alerts or mandate treatment changes. Participants will not concurrently receive the broader project's home-monitoring and clinical-alert intervention during this feasibility study. Usual clinical care will continue.

06

What researchers measure

Primary outcomes

  1. Feasibility of Digital Implementation

    Percentage of all enrolled participants who answer at least 80% of the 74 items in the baseline digital questionnaire battery comprising the EORTC QLQ-C30 and FACT-Leu within 7 days after the baseline visit. Meeting this criterion requires at least 60 answered items. The numerator will include participants meeting this criterion, and the denominator will include all enrolled participants. Responses saved within the assessment window will count irrespective of formal battery submission. Participants with fewer than 60 answered items, including those with no recorded responses, will not meet the criterion. Individual items may be skipped; the 74-item denominator does not imply mandatory responses. The percentage will be reported with a 95% confidence interval.

    Time frame: Within 7 days after the baseline visit.

Secondary outcomes

  1. Caregiver Assistance Requirement

    Proportion of participants requiring practical caregiver assistance to access or navigate the platform, read questionnaire content or enter responses selected by the participant. Independent proxy completion will not be permitted.

    Time frame: Within 7 days after the baseline visit.

  2. Non-completion of Planned Digital Follow-up Assessment

    Proportion of all enrolled participants who do not answer at least 60 of the 74 items in the EORTC QLQ-C30 and FACT-Leu follow-up digital questionnaire battery during the assessment window of 8-12 weeks after individual digital pathway activation. Completion will be determined from responses saved within this window, irrespective of formal battery submission. Participants with fewer than 60 answered items, including those with no recorded follow-up responses, will be classified as not completing the follow-up assessment. Reasons will be recorded where ascertainable, including voluntary withdrawal, technical difficulties, clinical deterioration, disease progression, hospitalization, death, and loss to follow-up, and reported separately.

    Time frame: 8-12 weeks after individual digital pathway activation.

  3. Elapsed Time to Reach the Baseline Questionnaire Completion Threshold

    Elapsed time, in minutes, between the first saved item response in the baseline digital questionnaire battery and the first time at which at least 60 distinct items out of 74 have saved responses. This measure will be calculated among participants who reach this threshold within 7 days after the baseline visit, using platform timestamps. Elapsed time will include pauses and intervals between sessions and will not be interpreted as active questionnaire completion time. Participants who do not reach the threshold will not be assigned a completion time; their number will be reported separately.

    Time frame: Within 7 days after the baseline visit.

07

Study locations

1 site
  • Hospital Universitario Central de Asturias (HUCA)
    Oviedo, Principality of Asturias 33011, Spain
    • Hospital Universitario Central de Asturias (HUCA) · Contact+34985108000
08

References and documents

Publications

  • Woods JD, Klepin HD. Geriatric Assessment in Acute Myeloid Leukemia. Acta Haematol. 2024;147(2):219-228. doi: 10.1159/000535500. Epub 2023 Nov 30. PubMed 38035561 ↗
  • Franzoi MA, Ferreira AR, Lemaire A, Rodriguez J, Grosjean J, Ribeiro JM, Polastro L, Grellety T, Artignan X, Le Du K, Pagliuca M, Nouhaud E, Autheman M, Andre F, Basch E, Metzger O, Ferte C, Di Palma M, Scotte F, Vaz-Luis I. Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium. Lancet Reg Health Eur. 2024 Jul 31;44:101005. doi: 10.1016/j.lanepe.2024.101005. eCollection 2024 Sep. PubMed 39444707 ↗
  • Aanes SG, Wiig S, Nieder C, Haukland EC. Implementing digital patient-reported outcomes in routine cancer care: barriers and facilitators. ESMO Real World Data Digit Oncol. 2024 Oct 23;6:100088. doi: 10.1016/j.esmorw.2024.100088. eCollection 2024 Dec. PubMed 41646091 ↗
  • Peipert JD, Efficace F, Pierson R, Loefgren C, Cella D, He J. Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia. J Geriatr Oncol. 2022 Sep;13(7):935-939. doi: 10.1016/j.jgo.2021.09.007. Epub 2021 Sep 11. PubMed 34521609 ↗
  • Basch E, Rocque G, Mody G, Mullangi S, Patt D. Tenets for Implementing Electronic Patient-Reported Outcomes for Remote Symptom Monitoring During Cancer Treatment. JCO Clin Cancer Inform. 2023 Feb;7:e2200187. doi: 10.1200/CCI.22.00187. PubMed 36857630 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying results reported in publications arising from this study, together with the corresponding data dictionary and statistical analysis code, will be available from the principal investigators upon reasonable request. Access will be subject to a methodologically sound proposal, institutional governance review, an appropriate data-use agreement and applicable ethics and data-protection requirements. Owing to the small sample size and risk of re-identification, participant-level data will not be deposited in an openly accessible public repository.

Supporting information: Study protocol, Analytic code

Time frame: Beginning 6 months after publication of the principal study results and ending 5 years thereafter.

Access criteria: Requests must include a methodologically sound research proposal and will be subject to approval by the principal investigators and relevant institutional governance bodies. Access will require an appropriate data-use agreement and compliance with applicable ethics and data-protection requirements

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 12 months is below that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2028 → Mar 2028, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 19, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2028was Jun 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jun 2028→Mar 2028
Oct 7, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameFeasibility of Digital ImplementationWithin 7 days after baseline. → Within 7 days after the baseline visit.
  • DescriptionFeasibility of Digital Implementation: how it is measured was reworded
Oct 7, 2026
Secondary outcomes
1 edited, 2 time frame changed, 1 description edited
What changed in the outcomes
  • ChangedBefore Time Required for Digital CompletionNow Elapsed Time to Reach the Baseline Questionnaire Completion ThresholdTime frame: Within 7 days after baseline. → Within 7 days after the baseline visit.
  • Time frameCaregiver Assistance RequirementWithin 7 days after baseline. → Within 7 days after the baseline visit.
  • Time frameNon-completion of Planned Digital Follow-up AssessmentFrom baseline to 3-6 months. → 8-12 weeks after individual digital pathway activation.
  • DescriptionNon-completion of Planned Digital Follow-up Assessment: how it is measured was reworded
Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hospital Universitario Central de Asturias (HUCA) · Oviedo, SpainContact added •••8000
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Study completion Jun 2028→Mar 2028
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameFeasibility of Digital ImplementationWithin 7 days after baseline. → Within 7 days after the baseline visit.
    • DescriptionFeasibility of Digital Implementation: how it is measured was reworded
    Secondary outcomes 1 edited, 2 time frame changed, 1 description edited
    What changed in the outcomes
    • ChangedBefore Time Required for Digital CompletionNow Elapsed Time to Reach the Baseline Questionnaire Completion ThresholdTime frame: Within 7 days after baseline. → Within 7 days after the baseline visit.
    • Time frameCaregiver Assistance RequirementWithin 7 days after baseline. → Within 7 days after the baseline visit.
    • Time frameNon-completion of Planned Digital Follow-up AssessmentFrom baseline to 3-6 months. → 8-12 weeks after individual digital pathway activation.
    • DescriptionNon-completion of Planned Digital Follow-up Assessment: how it is measured was reworded
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hospital Universitario Central de Asturias (HUCA) · Oviedo, SpainContact added •••8000
    + 5 other changes: verification date, description, conditions, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07597590
Lead sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Responsible party
Teresa Bernal del Castillo (PhD, Fundación para la Investigación Biosanitaria del Principado de Asturias) — Principal investigator
First posted
May 19, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Maria Antuna-Casal, PhD
Contact
antunamaria@uniovi.es
+34 661446805
Maria Antuna
Contact
antunamaria@uniovi.es

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion